Calls Now Open
2024 ADDF-Harrington + 2025 Harrington Scholar-Innovator Programs
May 01, 2024
Harrington Discovery Institute at University Hospitals is now accepting Letters of Intent for the 2025 Harrington Scholar-Innovator Award for physician-scientists. The award offers successful applicants multiple opportunities for funding in addition to expertise from pharma-experienced leaders with a track record of bringing...
Continue ReadingDecember 08, 2023
Similar technology is gaining regulatory approval to treat sickle cell disease and drawing research attention to treat a wide range of health concerns Continue Reading
December 05, 2023
New cause of diabetes discovered, offering potential target for new classes of drugs to treat the disease Continue Reading
November 30, 2023
Sol-Gel Technologies, a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, begun Phase 3 testing of SGT-610 for Gorlin syndrome with the first patient screened. Continue Reading
October 25, 2023
ABX1100 is a first-in-class molecule representing a new approach to reducing toxic levels of glycogen that build up in muscles of patients with Pompe Disease. Continue Reading
October 18, 2023
First Ten Years. Accelerating Discoveries into Medicines. Continue Reading
October 04, 2023
Monoclonal antibodies could provide a much-needed tool to protect vulnerable populations from severe COVID-19 Continue Reading
October 03, 2023
The Therapeutics Accelerator will identify, fund and advance innovative projects from academic partners in the U.K. and U.S. with the goal to deliver 40 new potentially life-changing therapies for rare diseases into clinical trials over 10 years. Continue Reading
September 29, 2023
Aleta hopes to initiate the registrational trial investigating ALETA-001 in B-cell malignancies in 2024/25. Continue Reading
September 23, 2023
Agreement enables the development of therapeutics, including AcuraStem's AS-202 Candidate, an antisense oligonucleotide that suppresses levels of the PIKFYVE kinase Continue Reading
September 14, 2023
New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC) Continue Reading